局部晚期前列腺癌长期雄激素剥夺治疗联合或不联合放疗:一项III期随机试验的更新结果
这项多中心III期随机试验纳入263例局部晚期前列腺癌患者,随机接受单纯雄激素剥夺治疗(ADT)或ADT联合外照射放疗(EBRT),随访中位7.3年。ADT+EBRT组8年无进展生存率显著高于ADT组(48% vs 7%;HR 0.27,95%CI 0.17-0.39;P<0.001),前列腺癌死亡风险显著降低(SHR 0.48,95%CI 0.25-0.91;P=0.02),但8年总生存率两组无显著差异(ADT组57% vs ADT+EBRT组65%)。
要点
- ADT+EBRT组8年无进展生存率48%,显著高于ADT组的7%(HR 0.27,95%CI 0.17-0.39;P<0.001)。
- ADT+EBRT组前列腺癌死亡风险显著降低(SHR 0.48,95%CI 0.25-0.91;P=0.02)。
- 8年总生存率ADT组57% vs ADT+EBRT组65%,无显著差异;无转移生存两组相当(P=0.88)。
核心结论
- 长期结果证实,在局部晚期前列腺癌治疗中,EBRT联合ADT具有肿瘤学获益。
研究设计与样本
- 多中心III期随机试验,纳入263例局部晚期前列腺癌患者,随机分配至ADT单药组或ADT+EBRT组。
- 亮丙瑞林11.25 mg给药3年;全骨盆照射剂量46 Gy,前列腺推量20至28 Gy。
- 主要终点为无进展生存(PFS);次要终点包括总生存(OS)、疾病特异性生存(DSS)、局部区域无进展生存(LRPFS)、无转移生存(MFS)、生化无进展生存(BPFS)和耐受性。
主要发现
- 中位随访7.3年,ADT+EBRT组8年PFS率48% vs ADT组7%(HR 0.27,95%CI 0.17-0.39;P<0.001)。
- 基线PSA≥50 ng/mL患者中HR 0.10(95%CI 0.05-0.20;P<0.001);基线PSA<50 ng/mL患者中HR 0.28(95%CI 0.19-0.40;P<0.001)。
- ADT+EBRT组前列腺癌死亡风险显著降低(SHR 0.48,95%CI 0.25-0.91;P=0.02)。
- 8年OS率ADT组57% vs ADT+EBRT组65%,无显著差异;LRPFS显著有利于ADT+EBRT组(SHR 0.61,95%CI 0.42-0.89;P=0.01);MFS两组相当(P=0.88)。
- ADT+EBRT组急性期耐受性较低,EBRT结束后6个月起强度逐渐减轻。
关键数值与推荐
- ADT+EBRT组8年PFS率48% vs ADT组7%(HR 0.27,95%CI 0.17-0.39;P<0.001)。
- 基线PSA≥50 ng/mL患者HR 0.10(95%CI 0.05-0.20;P<0.001);基线PSA<50 ng/mL患者HR 0.28(95%CI 0.19-0.40;P<0.001)。
- 前列腺癌死亡SHR 0.48(95%CI 0.25-0.91;P=0.02)。
- 8年OS率ADT组57% vs ADT+EBRT组65%,无显著差异;LRPFS的SHR 0.61(95%CI 0.42-0.89;P=0.01);MFS组间P=0.88。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the long-term oncological outcomes of a randomised trial comparing androgen-deprivation therapy (ADT) combined with external beam radiation therapy (EBRT) and ADT alone in patients with locally advanced prostate cancer. PATIENTS AND METHODS: In this multicentre phase III trial, patients were randomly assigned to ADT alone or ADT+EBRT. Leuprorelin 11.25 mg was administered for 3 years. The whole pelvis was treated at a dose of 46 Gy and the prostate with a boost from 20 to 28 Gy. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), disease-specific survival (DSS), locoregional PFS (LRPFS), metastasis-free survival (MFS), biochemical PFS (BPFS), and tolerance. RESULTS: With a median follow-up of 7.3 years, 263 patients were included. The 8-year PFS rate was significantly higher in the ADT+EBRT arm than in the ADT arm (48% vs 7%; hazard ratio [HR] 0.27, 95% confidence interval [CI] 0.17-0.39; P < 0.001); in patients with a baseline PSA level ≥50 ng/mL (HR 0.10, 95% CI 0.05-0.20; P < 0.001) and in patients with a baseline PSA level <50 ng/mL (HR 0.28, 95% CI 0.19-0.40; P < 0.001). The risk of death from prostate cancer was significantly reduced in the ADT+EBRT arm (sub-HR [SHR] 0.48, 95% CI 0.25-0.91; P = 0.02). The 8-year OS rate was 57% in the ADT arm and 65% in the ADT+EBRT arm (no significant difference). LRPFS was significantly in favour of the ADT+EBRT arm (SHR 0.61, 95% CI 0.42-0.89; P = 0.01). MFS was comparable between both arms (P = 0.88). Analysis of toxicities revealed acute lower tolerance in the ADT+EBRT arm, with a gradual decrease in intensity from 6 months after the end of EBRT. CONCLUSIONS: These long-term results confirm the oncological benefit of combining EBRT with ADT in the treatment of locally advanced prostate cancer.
引用
- Sargos P, Mottet N, Bellera C, et al. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial. BJU Int. 2020. PMID: 30946523. doi:10.1111/bju.14768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。